168 related articles for article (PubMed ID: 35798977)
1. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
[TBL] [Abstract][Full Text] [Related]
2. Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.
Zheng X; He X; Yang Y; Liu X; Zhang LL; Qu BL; Zhong QZ; Qian LT; Hou XR; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Zhang HL; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; Chen F; Yin L; Qi SN; Li YX
ESMO Open; 2021 Aug; 6(4):100206. PubMed ID: 34242966
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
[TBL] [Abstract][Full Text] [Related]
4. Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation.
Qi F; Zhou W; Xie Y; Sun Y; Wu M; Chai Y; Chen B; Lin N; Liu W; Ding N; Li Y; Dong M; Song Y; Zhu J
Aging (Albany NY); 2022 Nov; 14(21):8729-8744. PubMed ID: 36326691
[TBL] [Abstract][Full Text] [Related]
5. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.
Qi SN; Yang Y; Song YQ; Wang Y; He X; Hu C; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Huang HQ; Zhang YJ; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Zhu J; Li YX
Blood Adv; 2020 Jul; 4(13):3141-3153. PubMed ID: 32658985
[TBL] [Abstract][Full Text] [Related]
6. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Kwong YL; Kim SJ; Tse E; Oh SY; Kwak JY; Eom HS; Do YR; Mun YC; Lee SR; Shin HJ; Suh C; Chuang SS; Lee YS; Lim ST; Izutsu K; Suzuki R; Relander T; d'Amore F; Schmitz N; Jaccard A; Kim WS
Ann Oncol; 2018 Jan; 29(1):256-263. PubMed ID: 29077846
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
8. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
[TBL] [Abstract][Full Text] [Related]
9. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
[TBL] [Abstract][Full Text] [Related]
10. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
11. Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
Deng XW; Wu JX; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Dong M; Qi SN; Yang Y; Li YX
Radiother Oncol; 2018 Oct; 129(1):3-9. PubMed ID: 29739712
[TBL] [Abstract][Full Text] [Related]
13. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
14. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
[TBL] [Abstract][Full Text] [Related]
17. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
[TBL] [Abstract][Full Text] [Related]
18. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
19. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
